A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness

Kheshti, Raziyeh; Aalipour, Mohammadsadegh; Namazi, Soha

doi:10.4103/2279-042x.192461

Cited by 151 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, it is a known problem that different DDI screening tools offer different sensitivity and specificity. Furthermore, it has also been reported that DDI databases under-report clinically relevant DDIs and in some cases, over report insignificant drug interactions [ 59 , 60 ].…”

Section: Discussionmentioning

confidence: 99%

Patterns and Characteristics of Polypharmacy Among Elderly Residents in Danish Nursing Homes

et al. 2020

View full text Add to dashboard Cite

Aim: To identify patterns and characteristics of polypharmacy among elderly residents in Danish nursing homes in the Northern region of Denmark. Materials & methods: Twenty-five nursing homes were contacted, where each supplied 20 randomly selected anonymized residents’ information. Residents were 65 years or older, concurrently taking five or more medications. Drug–drug interactions and potential adverse effects were investigated. Results: One hundred residents (68% females; 32% males) were included. The most prevalent co-morbid condition was cardiovascular disease, and the most prevalent medications were for gastrointestinal- and metabolism-related conditions. Age influenced the number of drugs (p = 0.013) and drug–drug interactions per resident (p = 0.039), with a positive correlation. Conclusion: Elderly residents of the studied nursing homes were potentially affected by an inappropriate polypharmacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Patterns and Characteristics of Polypharmacy Among Elderly Residents in Danish Nursing Homes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Educational outreach is one possible solution, although the fact that 79.1% of the participants in this study had recently undergone CME in pain management dampens enthusiasm. Software tools have been shown to help [ 22 ] as have team-based approaches involving pharmacists [ 23 ]. More of these solutions could be implemented.…”

Section: Discussionmentioning

confidence: 99%

Drug-Drug Interaction Assessment and Identification in the Primary Care Setting

et al. 2018

View full text Add to dashboard Cite

BackgroundDrug-drug interactions (DDIs) are ubiquitous, harmful and a leading cause of morbidity and mortality. With an aging population, growth in polypharmacy, widespread use of supplements, and the rising opioid abuse epidemic, primary care physicians (PCPs) are increasingly challenged with identifying and preventing DDIs. We set out to evaluate current clinical practices related to identifying and treating DDIs and to determine if opportunities to increase prevention of DDIs and their adverse events could be identified.MethodsIn a nationally representative sample of 330 board-certified family and internal medicine practitioners, we evaluated whether PCPs assessed DDIs in the care they provided for three simulated patients. The patients were taking common prescription medications (e.g. opioids and psychiatric medications) along with other common ingestants (e.g. supplements and food) and presented with symptoms of DDIs. Physicians were scored on their ability to inquire about the patient’s medications, investigate possible DDIs, evaluate the patient, and provide treatment recommendations. We scored the physicians’ care recommendations against evidence-based criteria, including overall care quality and treatment for DDIs.ResultsAverage overall quality of care score was 50.5% ± 12.0%. Despite >99% self-reported use of medication reconciliation practices and tools, physicians identified DDIs in only 15.3% of patients, with 15.5% ± 20.3% of DDI-specific treatment by the physicians.ConclusionsPCPs in this study did not recognize or adequately treat DDIs. Better methods are needed to screen for DDIs in the primary care setting.

show abstract

“… An interaction check was undertaken between clozapine and all medicines, using Lexicomp ® [ 13 ] and Stockley’s Interaction Checker (SIC) [ 14 ]. Lexicomp ® is a widely accessible drug interaction software program and studies show it provides the most competent, complete, and user-friendly applications [ 15 ]. SIC is a comprehensive and authoritative international reference book on DDIs.…”

Section: Methodsmentioning

confidence: 99%

Clozapine Patients at the Interface between Primary and Secondary Care

et al. 2018

View full text Add to dashboard Cite

Patients receiving clozapine must undergo routine blood monitoring to screen for neutropenia, and to monitor for potential agranulocytosis. In Cork University Hospital, Cork, Ireland, clozapine is dispensed in the hospital pharmacy and the pharmacists are not aware of co-prescribed medicines, potentially impacting upon patient safety. The aim of this study was to examine the continuity of care of patients prescribed clozapine. A retrospective audit was conducted on patients attending the clozapine clinic at Cork University Hospital and assessed patients’ (i) independent living, (ii) co-prescribed medicines and (iii) knowledge of their community pharmacists regarding co-prescribed clozapine. A list of prescribed medicines for each patient was obtained, and potential drug-drug interactions between these medicines and clozapine were examined using Lexicomp® and Stockley’s Interaction checker. Secondary outcomes included patients’ physical health characteristics, and a review of co-morbidities. Data were collected between the 29 May 2017 and 20 June 2017. Local ethics committee approval was granted. Patients were eligible for inclusion if they were receiving clozapine treatment as part of a registered programme, were aged 18 years or more, and had the capacity to provide written informed consent. Microsoft Excel was used for data analysis. Of 112 patients, (33% female; mean age (SD) 43.9 (11.3) years; 87.5% living independently/in the family home) 86.6% patients reported that they were taking other prescribed medicines from community pharmacies. The mean (SD) number of co-prescribed medicines in addition to clozapine was 4.8 (4) per patient. Two thirds of community pharmacists were unaware of co-prescribed clozapine. Interactions with clozapine were present in all but 3 patients on co-prescribed medicines (n = 97). Lexicomp® reported 2.9 drug-drug interactions/patient and Stockley’s Interaction Checker reported 2.5 drug-drug interactions/patient. Secondary outcomes for patients included BMI, total cholesterol, and HbA1c levels, which were elevated in 75%, 54% and 17% respectively. Patients prescribed clozapine did not receive a seamless service, between primary and secondary care settings. Community pharmacists were not informed of clozapine, prescribed for their patients, in two thirds of cases. Patients in this study were exposed to clozapine-related drug-drug interactions and hence potential adverse effects. This study supports reports in the literature of substandard management of the physical health of this patient group. This study shows that there is an opportunity for pharmacists to develop active roles in the management of all clozapine-related effects, in addition to their traditional obligatory role in haematological monitoring. This study supports the need for a clinical pharmacist to review inpatients commencing on clozapine, monitor for drug-drug interactions and provide counselling.

show abstract

A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness

Cited by 151 publications

References 22 publications

Patterns and Characteristics of Polypharmacy Among Elderly Residents in Danish Nursing Homes

Patterns and Characteristics of Polypharmacy Among Elderly Residents in Danish Nursing Homes

Drug-Drug Interaction Assessment and Identification in the Primary Care Setting

Clozapine Patients at the Interface between Primary and Secondary Care

Contact Info

Product

Resources

About